BioCentury | Jun 4, 2012
Finance

Agendia's private party

...hoped to raise €75 million ($110 million). Existing investors Gilde Healthcare Partners; Van Herk Group; ING Corporate Investments...
BioCentury | Jun 1, 2012
Financial News

Agendia raises $65 million

...by Debiopharm Group . All existing investors participated, including Gilde Healthcare Partners; Van Herk Group; ING Corporate Investments...
BioCentury | Apr 2, 2012
Finance

Celling the liver

...issues that have plagued cell therapy play TiGenix N.V. (Euronext:TIG), where he invested while at ING Corporate Investments...
BioCentury | Jun 13, 2011
Finance

Agendia's agenda

...€5 million ($7.3 million) of shares at the offer price. Shareholders include Breedinvest; Gilde Healthcare; ING Corporate Investments...
BioCentury | Dec 3, 2007
Company News

TiGenix board of directors update

...Appointed: Willy Duron, a director, as chairman; and Luc Van de Steen, investment director at ING Corporate Investments...
Items per page:
1 - 5 of 5
BioCentury | Jun 4, 2012
Finance

Agendia's private party

...hoped to raise €75 million ($110 million). Existing investors Gilde Healthcare Partners; Van Herk Group; ING Corporate Investments...
BioCentury | Jun 1, 2012
Financial News

Agendia raises $65 million

...by Debiopharm Group . All existing investors participated, including Gilde Healthcare Partners; Van Herk Group; ING Corporate Investments...
BioCentury | Apr 2, 2012
Finance

Celling the liver

...issues that have plagued cell therapy play TiGenix N.V. (Euronext:TIG), where he invested while at ING Corporate Investments...
BioCentury | Jun 13, 2011
Finance

Agendia's agenda

...€5 million ($7.3 million) of shares at the offer price. Shareholders include Breedinvest; Gilde Healthcare; ING Corporate Investments...
BioCentury | Dec 3, 2007
Company News

TiGenix board of directors update

...Appointed: Willy Duron, a director, as chairman; and Luc Van de Steen, investment director at ING Corporate Investments...
Items per page:
1 - 5 of 5